^
Association details:
| Biomarker: | CHEK1 mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | hydroxyureamethylacylfulvene (STAR-001) (Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LP-184, a Tumor Site Activated Small Molecule Acylfulvene, Is Effective Preclinically in Subsets of Lung Cancer
Published date:
08/08/2023
Excerpt:
LP-184 displayed strong nanomolar potency in 7 day ex vivo treatment in a panel of patient derived lung cancer models carrying ATM, BRCA1 or CHEK1 mutations with IC50s in the range of 30 - 200 nM, which turned out to be 12-350 times superior to that of Olaparib across the same models.
